News | November 08, 2013

Zevacor Molecular Awards IBA Contract to Build Only U.S. Commercial Cyclotron for Sr-82 Production

Cyclone 70 to stabilize U.S. supply of strontium 82/rubidium 82 generators for use in diagnosis of cardiovascular disease

cyclone 70 zevacor IBM nuclear imaging radiopharmaceuticals and tracers PET
November 8, 2013 — Zevacor Molecular, a healthcare firm that manufactures and distributes positron emissions tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A. (IBA).
 
The purchase of IBA’s Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses. 
 
Strontium 82 (Sr-82) has a half-life of about 25 days, allowing it to be easily shipped to imaging facilities for about a month of use. It is shipped as a generator unit to produce rubidium 82 (Rb-82) at the point of imaging, since Rb-82 has a half-life of only 75 seconds. The isotope is primarily used for nuclear myocardial perfusion exams.
 
In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a state-of-the-art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. It expects to determine the location by the end of 2013.
 
“This is just the beginning,” said John Zehner, executive vice president and chief operating officer, Zevacor Molecular. “With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics.”
 
The main focus of the first 70 MeV Cyclotron will be to commercially manufacture Sr-82 to ensure ample, stable, U.S.-based supply of Sr-82/Rb-82 generators for use in the diagnosis of cardiovascular disease. This important radiotracer has no current commercial supplier and only has U.S. and foreign-based supply from national labs.
 
Although the primary focus is the manufacture of Sr-82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 
 
For more information: www.zevacor.com, www.iba-worldwide.com

Related Content

Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init